
June 2 (Reuters) - Amgen Inc AMGN.O:
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
AMGEN INC - IMDELLTRA SHOWS SURVIVAL ADVANTAGE OVER STANDARD CHEMOTHERAPY
AMGEN INC - IMDELLTRA EXTENDS MEDIAN OVERALL SURVIVAL TO 13.6 MONTHS